Category: FDA & Regulatory Policy (Page 3)

January 3, 2017

Alliance Issues Statement on the Protect Medical Innovation Act of 2017

The Alliance has issued the following statement from President and CEO Susan Peschin, MHS, regarding the introduction of the Protect Medical Innovation Act of 2017
December 15, 2016

AIM Coalition Held Second Annual Meeting

On December 2, the Aging in Motion (AIM) Coalition hosted its second annual meeting in Bethesda, Md., to discuss developments and advances in clinical research and treatment of sarcopenia.
December 7, 2016

Alliance Releases Statement on Passage of 21st Century Cures

The Senate today approved landmark legislation overhauling the development of medical treatments and cures for patients, which represents the culmination of a multi-year, bipartisan initiative in Congress. Here is a statement from Alliance President and CEO Sue Peschin.
December 2, 2016

AIM Coalition Meeting Spotlights Sarcopenia Research Advances

The Aging in Motion (AIM) Coalition hosted its second annual meeting with U.S. Food and Drug Administration (FDA) leaders and leading scientists, industry representatives, and advocates to discuss developments and advances in clinical research and treatment of sarcopenia in Bethesda, Md.
November 22, 2016

ACT-AD Coalition Holds Ninth Annual Meeting

On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.
November 16, 2016

Experts Explore Federal Agency Collaborations to Close Alzheimer’s Disease Research Gaps at ACT-AD Coalition Annual Meeting

Today, senior representatives from the U.S. Food and Drug Administration (FDA) and the National Institute on Aging at the National Institutes of Health (NIH) joined with advocates, federal colleagues, researchers, and industry to explore collaborations for advancing the most up-to-date knowledge in Alzheimer’s disease research. 
October 31, 2016

An Update on 21st Century Cures

We provide an update on the 21st Century Cures Act, an important piece of legislation that the Alliance has been advocating for.
October 31, 2016

ACT-AD Will Host Ninth Annual Meeting

The ACT-AD Coalition will host its Ninth Annual FDA/Alzheimer's Disease Allies Meeting on November 16, 2016. 
August 30, 2016

Alliance Comments on the FDA’s Commitment Letter for PDUFA VI

In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.
August 23, 2016

Alliance Comments on PDUFA VI Commitment Letter

The Alliance provided comments in response to the U.S. Food and Drug Administration's PDUFA VI Commitment Letter.